261 related articles for article (PubMed ID: 28405501)
21. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
22. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
Bertucci F; Finetti P; Birnbaum D; Mamessier E
Oncoimmunology; 2016 Mar; 5(3):e1085148. PubMed ID: 27141340
[TBL] [Abstract][Full Text] [Related]
23. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
24. VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
Albertsmeier M; Altendorf-Hofmann A; Lindner LH; Issels RD; Kampmann E; Dürr HR; Angele MK; Klauschen F; Werner J; Jungbluth AA; Knösel T
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205752
[TBL] [Abstract][Full Text] [Related]
25. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.
Nowicki TS; Anderson JL; Federman N
Pediatr Res; 2016 Mar; 79(3):371-7. PubMed ID: 26595537
[TBL] [Abstract][Full Text] [Related]
26. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
27. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
28. Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values.
Ledoux P; Kind M; Le Loarer F; Stoeckle E; Italiano A; Tirode F; Buy X; Crombé A
Eur J Radiol; 2019 Aug; 117():112-119. PubMed ID: 31307635
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
30. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.
Lesluyes T; Pérot G; Largeau MR; Brulard C; Lagarde P; Dapremont V; Lucchesi C; Neuville A; Terrier P; Vince-Ranchère D; Mendez-Lago M; Gut M; Gut I; Coindre JM; Chibon F
Eur J Cancer; 2016 Apr; 57():104-11. PubMed ID: 26916546
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics and prognostic factors of T1 (≤5 cm) soft tissue sarcoma -- a comparative study with T2 (>5 cm) soft tissue sarcoma.
Kang S; Han I; Lee S; Kim W; Kim H
Eur J Surg Oncol; 2014 Apr; 40(4):406-11. PubMed ID: 24388741
[TBL] [Abstract][Full Text] [Related]
32. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
[TBL] [Abstract][Full Text] [Related]
33. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
34. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
Front Oncol; 2021; 11():759497. PubMed ID: 34868974
[TBL] [Abstract][Full Text] [Related]
35. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D; Sundaram S; N K; R P
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis.
Bourcier K; Dinart D; Le Cesne A; Honoré C; Meeus P; Blay JY; Michot A; Le Loarer F; Italiano A
Oncologist; 2019 Jul; 24(7):e559-e564. PubMed ID: 31015315
[TBL] [Abstract][Full Text] [Related]
38. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
Wu Z; Zhang L; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Lu J; Yin W; Lu J
Cancer Biol Ther; 2019; 20(6):941-947. PubMed ID: 30866717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
